Carbamazepine Treatment for Cocaine Dependence - 5
Phase 2
Completed
- Conditions
- Cocaine-Related Disorders
- Registration Number
- NCT00000191
- Lead Sponsor
- University of Pennsylvania
- Brief Summary
The purpose of this study is to assess carbamazepine as a pharmacotherapy for cocaine dependence.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie carbamazepine's efficacy in treating cocaine dependence as studied in NCT00000191?
How does carbamazepine compare to standard-of-care medications like bupropion or naltrexone for cocaine dependence?
Are there specific biomarkers identified in NCT00000191 that predict patient response to carbamazepine treatment?
What adverse events were observed in NCT00000191 and how do they compare to other anticonvulsants used in addiction therapy?
What combination therapies or alternative drugs have been explored alongside carbamazepine for cocaine use disorder since 1991?
Trial Locations
- Locations (1)
University of Pennsylvania
🇺🇸Philadelphia, Pennsylvania, United States
University of Pennsylvania🇺🇸Philadelphia, Pennsylvania, United States